The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Jul 2017 07:00

RNS Number : 5054M
Silence Therapeutics PLC
31 July 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Silence Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 July 2017

6. Date on which issuer notified:

28 July 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 > 25,26

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B9GTXM62

17,458,481

17,458,481

18,838,695

18,838,695

26.92%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

18,838,695

26.92%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Blake Holdings Limited

7,550,731

Seren Investment Management Limited

8,223,507

Oak Trust Limited

182,837

Richard Griffiths - indirect holdings

692,153

Sarossa Plc

2,189,467

Total

18,838,695

 

 

The above undertakings are all controlled by Richard Griffiths

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+ 44 1534 719 761

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURSVRBRABOAR
Date   Source Headline
30th Mar 20167:00 amRNSHolding(s) in Company
22nd Mar 20167:00 amRNSNotice of Results
18th Jan 20167:00 amRNSBoard changes
12th Nov 20157:00 amRNSBoard appointment
30th Oct 20152:32 pmRNSLicensee's drug to commence Ph 2/Ph 3 trials
29th Sep 20157:00 amRNSInterim Results
22nd Sep 20157:19 amRNSBoard Change and Notice of Results
30th Jul 20157:01 amRNSInterim Board Change
1st Jun 201511:42 amRNSResult of AGM
1st Jun 20157:00 amRNSAGM statement and clinical trial interim analysis
14th May 20159:55 amRNSReplacement: Holding(s) in Company
14th May 20157:00 amRNSClinical trial update
12th May 201510:19 amRNSHolding(s) in Company
11th May 20155:31 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 201511:29 amRNSHolding(s) in Company
11th May 201510:50 amRNSHolding(s) in Company
11th May 201510:06 amRNSNotice of AGM
8th May 20155:21 pmRNSHolding(s) in Company
1st May 201510:32 amRNSResult of General Meeting and Additional Listing
16th Apr 20155:48 pmRNSAdditional Listing
8th Apr 201511:33 amRNSFundraising update
2nd Apr 20152:34 pmRNSPreliminary results
2nd Apr 20152:34 pmRNSConditional fundraising of approximately £40m
23rd Mar 20157:00 amRNSClinical trial update
16th Feb 20157:00 amRNSPresentation at RNA Therapeutics conference
12th Feb 20157:00 amRNSSuccessful European patent appeal
27th Jan 20157:00 amRNSGrant of share options
5th Jan 20157:00 amRNSBoard Changes
15th Dec 20147:00 amRNSBoard appointment
1st Dec 20147:00 amRNSTrading update and capital markets presentation
1st Dec 20147:00 amRNSTechnology breakthrough
18th Nov 20147:00 amRNSPublication of study data
3rd Nov 201410:26 amRNSAdditional Listing
22nd Oct 20145:44 pmRNSNotification of Major Interest in Shares
23rd Sep 201411:41 amRNSAdditional Listing
16th Sep 20147:00 amRNSHalf year results
2nd Sep 20149:05 amRNSBoard change
27th Aug 20143:38 pmRNSNotice of Results
5th Aug 20147:00 amRNSPublication of pre-clinical study data
30th Jul 20147:00 amRNSLicensee confirms favourable trial outcome
18th Jul 20144:40 pmRNSSecond Price Monitoring Extn
18th Jul 20144:35 pmRNSPrice Monitoring Extension
17th Jul 20145:01 pmRNSNotification of major interest in shares
16th Jul 20147:00 amRNSCompletion of recruitment for phase 2a trial
9th Jul 20144:40 pmRNSSecond Price Monitoring Extn
9th Jul 20144:35 pmRNSPrice Monitoring Extension
3rd Jul 20144:35 pmRNSPrice Monitoring Extension
27th Jun 20144:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.